1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Intravesical Chemotherapy
1.2.3 Intravesical Immunotherapy
1.3 Market by Application
1.3.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Ambulatory Surgery Center
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Perspective (2017-2028)
2.2 Non-muscle Invasive Bladder Cancer Therapeutics Growth Trends by Region
2.2.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Non-muscle Invasive Bladder Cancer Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Non-muscle Invasive Bladder Cancer Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Non-muscle Invasive Bladder Cancer Therapeutics Market Dynamics
2.3.1 Non-muscle Invasive Bladder Cancer Therapeutics Industry Trends
2.3.2 Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers
2.3.3 Non-muscle Invasive Bladder Cancer Therapeutics Market Challenges
2.3.4 Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-muscle Invasive Bladder Cancer Therapeutics Players by Revenue
3.1.1 Global Top Non-muscle Invasive Bladder Cancer Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-muscle Invasive Bladder Cancer Therapeutics Revenue
3.4 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-muscle Invasive Bladder Cancer Therapeutics Revenue in 2021
3.5 Non-muscle Invasive Bladder Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Non-muscle Invasive Bladder Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Non-muscle Invasive Bladder Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-muscle Invasive Bladder Cancer Therapeutics Breakdown Data by Type
4.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Forecasted Market Size by Type (2023-2028)
5 Non-muscle Invasive Bladder Cancer Therapeutics Breakdown Data by Application
5.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2017-2028)
6.2 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2017-2022)
6.3 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2017-2028)
7.2 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2017-2022)
7.3 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2017-2022)
8.3 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2017-2028)
9.2 Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2017-2022)
9.3 Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2017-2022)
10.3 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 F. Hoffmann-La Roche Ltd. Company Detail
11.1.2 F. Hoffmann-La Roche Ltd. Business Overview
11.1.3 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.1.4 F. Hoffmann-La Roche Ltd. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.1.5 F. Hoffmann-La Roche Ltd. Recent Development
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Detail
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.2.4 Bristol-Myers Squibb Company Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.2.5 Bristol-Myers Squibb Company Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.3.4 AstraZeneca Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.3.5 AstraZeneca Recent Development
11.4 Pfizer Inc.
11.4.1 Pfizer Inc. Company Detail
11.4.2 Pfizer Inc. Business Overview
11.4.3 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.4.4 Pfizer Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.4.5 Pfizer Inc. Recent Development
11.5 GlaxoSmithKline plc.
11.5.1 GlaxoSmithKline plc. Company Detail
11.5.2 GlaxoSmithKline plc. Business Overview
11.5.3 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.5.4 GlaxoSmithKline plc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.5.5 GlaxoSmithKline plc. Recent Development
11.6 Sanofi S.A.
11.6.1 Sanofi S.A. Company Detail
11.6.2 Sanofi S.A. Business Overview
11.6.3 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.6.4 Sanofi S.A. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.6.5 Sanofi S.A. Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Detail
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.7.4 Novartis AG Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.7.5 Novartis AG Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Detail
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.8.4 Eli Lilly and Company Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.8.5 Eli Lilly and Company Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Detail
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.9.4 Merck & Co. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.9.5 Merck & Co. Recent Development
11.10 Viventia Bio Inc.
11.10.1 Viventia Bio Inc. Company Detail
11.10.2 Viventia Bio Inc. Business Overview
11.10.3 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.10.4 Viventia Bio Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.10.5 Viventia Bio Inc. Recent Development
11.11 Celgene Corporation
11.11.1 Celgene Corporation Company Detail
11.11.2 Celgene Corporation Business Overview
11.11.3 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.11.4 Celgene Corporation Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.11.5 Celgene Corporation Recent Development
11.12 Spectrum Pharmaceuticals, Inc.
11.12.1 Spectrum Pharmaceuticals, Inc. Company Detail
11.12.2 Spectrum Pharmaceuticals, Inc. Business Overview
11.12.3 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.12.4 Spectrum Pharmaceuticals, Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.12.5 Spectrum Pharmaceuticals, Inc. Recent Development
11.13 Herantis Pharma Plc.
11.13.1 Herantis Pharma Plc. Company Detail
11.13.2 Herantis Pharma Plc. Business Overview
11.13.3 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.13.4 Herantis Pharma Plc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.13.5 Herantis Pharma Plc. Recent Development
11.14 Taris Biomedical LLC
11.14.1 Taris Biomedical LLC Company Detail
11.14.2 Taris Biomedical LLC Business Overview
11.14.3 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.14.4 Taris Biomedical LLC Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.14.5 Taris Biomedical LLC Recent Development
11.15 Prometic Life Sciences Inc.
11.15.1 Prometic Life Sciences Inc. Company Detail
11.15.2 Prometic Life Sciences Inc. Business Overview
11.15.3 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.15.4 Prometic Life Sciences Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.15.5 Prometic Life Sciences Inc. Recent Development
11.16 Telormediz S.A.
11.16.1 Telormediz S.A. Company Detail
11.16.2 Telormediz S.A. Business Overview
11.16.3 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.16.4 Telormediz S.A. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.16.5 Telormediz S.A. Recent Development
11.17 Heat Biologics
11.17.1 Heat Biologics Company Detail
11.17.2 Heat Biologics Business Overview
11.17.3 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.17.4 Heat Biologics Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.17.5 Heat Biologics Recent Development
11.18 Altor BioScience
11.18.1 Altor BioScience Company Detail
11.18.2 Altor BioScience Business Overview
11.18.3 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.18.4 Altor BioScience Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.18.5 Altor BioScience Recent Development
11.19 Ferring B.V.
11.19.1 Ferring B.V. Company Detail
11.19.2 Ferring B.V. Business Overview
11.19.3 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.19.4 Ferring B.V. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.19.5 Ferring B.V. Recent Development
11.20 Cold Genesys Inc.
11.20.1 Cold Genesys Inc. Company Detail
11.20.2 Cold Genesys Inc. Business Overview
11.20.3 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.20.4 Cold Genesys Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2017-2022)
11.20.5 Cold Genesys Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
